StockNews.AI
CAMP
StockNews.AI
113 days

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

1. CAMP4 to present key findings at annual gene therapy meeting in May. 2. Preclinical data suggests promising potential of regRNA-targeting therapeutics. 3. CMP-CPS-001 shows interim safety data from Phase 1 trial of healthy volunteers. 4. CAMP4 focuses on genetic diseases through its innovative RAP Platform™. 5. Future regulatory approvals and market competition pose potential risks.

11m saved
Insight
Article

FAQ

Why Bullish?

CAMP4’s promising clinical data and upcoming presentations may boost investor confidence, similar to gains seen in successful biotech presentations in the past. A positive reception at the conference could lead to increased stock activity.

How important is it?

The article discusses significant advancements and upcoming presentations, directly correlating with CAMP4's trajectory, becoming a pivotal moment for their stock performance.

Why Short Term?

The immediate impact is tied to the upcoming presentations, which can generate rapid investor interest. Historical trends show stock surges post positive clinical announcements.

Related Companies

NXTCCRSPEDITSGMOBMRN
April 28, 2025 16:30 ET  | Source: CAMP4 Therapeutics Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three oral presentations at the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, LA, May 13 – 17, 2025. Details for the oral presentations are as follows: Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of Urea Cycle DisordersPresenter: Dan Tardiff, Ph.D.Session title: Oligonucleotide Therapeutics IISession date and time: Friday May 16, 2025, 3:45 PM - 5:40 PM CT Title: Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of SYNGAP1-Related DisordersPresenter: Dan Tardiff, Ph.D.Session title: Oligonucleotide Therapeutics IISession date and time: May 16, 2025, 3:45 PM - 5:40 PM CT Title: A First-in-Human Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study (SAD, MAD) in Healthy Volunteers to Evaluate the Safety and Tolerability of an Investigational Antisense Oligonucleotide Therapy (CMP-CPS-001) for the Treatment of Urea Cycle Diseases (UCDs): Interim Safety ReadoutPresenter: Yuri Maricich, M.D.Session title: Oligonucleotide Therapeutics IISession date and time: May 16, 2025, 3:45 PM - 5:40 PM CT The presentations will be made available on the CAMP4 website at https://investors.camp4tx.com/news-events/presentations simultaneously with the session. About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com. Forward-Looking Statements This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4’s plans and expectations regarding its ongoing Phase 1 clinical trial of CMP-CPS-001 and its intention to initiate the expansion into a Phase 1b clinical trial of CMP-CPS-001; the anticipated timing and results of the company’s ongoing and future clinical trials, including expectations regarding the timing of reporting data from the CMP-CPS-001 clinical trials; the expected timing for the company’s initiation of GLP toxicity studies relating to CAMP4’s SYNGAP1 program; the therapeutic potential of CAMP4’s product candidates; estimates regarding the size of patient populations; and cash runway guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other information the Company files with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts Investor Relations: Dan Ferry (US)LifeSci Advisorsdaniel@lifesciadvisors.com Sandya von der Weid (Europe)LifeSci Advisorssvonderweid@lifesciadvisors.com Media: Jason Braco, Ph.D.LifeSci Communicationsjbraco@lifescicomms.com

Related News